Cargando…

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial

BACKGROUND: Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%–4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer, the best biomarker strategy for the enrichment of a susceptible pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuler, M., Berardi, R., Lim, W.-T, de Jonge, M., Bauer, T. M., Azaro, A., Gottfried, M., Han, J.-Y., Lee, D. H., Wollner, M., Hong, D. S., Vogel, A., Delmonte, A., Akimov, M., Ghebremariam, S., Cui, X., Nwana, N., Giovannini, M., Kim, T. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720758/ https://www.ncbi.nlm.nih.gov/pubmed/32240796 http://dx.doi.org/10.1016/j.annonc.2020.03.293

Ejemplares similares

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts
por: Bang, Yung‐Jue, et al.
Publicado: (2019)

Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study
por: Chen, Xinhui, et al.
Publicado: (2021)

Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects
por: Cui, Xiaoming, et al.
Publicado: (2022)

Capmatinib-Associated Pseudoacute Kidney Injury in Nonsmall Cell Lung Cancer
por: Sandoval, Leticia, et al.
Publicado: (2023)

Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics
por: Guo, Matthew Z, et al.
Publicado: (2021)

Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma
por: Turpin, Anthony, et al.
Publicado: (2023)

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2019)

HPLC with Fluorescence and Photodiode Array Detection for Quantifying Capmatinib in Biological Samples: Application to In Vivo and In Vitro Studies
por: Zayed, Aref, et al.
Publicado: (2022)

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
por: Kunimasa, Kei, et al.
Publicado: (2021)

Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors
por: Esaki, Taito, et al.
Publicado: (2019)

Capmatinib suppresses LPS-induced interaction between HUVECs and THP-1 monocytes through suppression of inflammatory responses
por: Park, Hyung Sub, et al.
Publicado: (2023)

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer
por: McCoach, Caroline E., et al.
Publicado: (2021)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC
por: Cravero, Paola, et al.
Publicado: (2020)

Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2‐drug cocktail in patients with MET‐dysregulated advanced solid tumours: A phase I, multicentre, open‐label, single‐sequence drug–drug interaction study
por: Grande, Enrique, et al.
Publicado: (2020)

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
por: Qin, Shukui, et al.
Publicado: (2019)

Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Publicado: (2020)

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
por: Tan, Aaron C, et al.
Publicado: (2021)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
por: Lefler, Daniel S, et al.
Publicado: (2022)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
por: Fraser, Madison, et al.
Publicado: (2023)

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
por: Schneider, Jaime L., et al.
Publicado: (2023)

The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
por: Choi, Wonyoung, et al.
Publicado: (2021)

Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
por: Gautschi, Oliver, et al.
Publicado: (2021)

MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report
por: Choi, Wonyoung, et al.
Publicado: (2022)

Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis
por: Kim, Tae Woo, et al.
Publicado: (2022)

The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
por: Hsu, Robert, et al.
Publicado: (2023)

Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping
por: Yang, Mo, et al.
Publicado: (2023)

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
por: Seto, Takashi, et al.
Publicado: (2021)

Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
por: Lin, Chien-Yu, et al.
Publicado: (2022)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
por: Wilgucki, Molly, et al.
Publicado: (2022)

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
por: Illini, Oliver, et al.
Publicado: (2022)

Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
por: Chou, Yun-Tse, et al.
Publicado: (2022)

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
por: Bauer, S, et al.
Publicado: (2014)

The endotoxin-induced pulmonary inflammatory response is enhanced during the acute phase of influenza infection
por: Koch, R. M., et al.
Publicado: (2018)

Prevalence of bovine tuberculosis in cattle, goats, and camels of traditional livestock raising communities in Eritrea
por: Ghebremariam, Michael K., et al.
Publicado: (2018)

Management of Posterior Reversible Syndrome in Preeclamptic Women
por: Poma, S., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2eoqa16tsoh5l7emsigvl7fjnv